Bistos
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Bistos makes medical devices that monitor and care for unborn babies and newborns, including fetal heartbeat monitors, jaundice treatment units, and infant incubators, as well as breast pumps and general patient-monitoring equipment for broader clinical and home use.
Its products reach hospitals, clinics, and consumers across a wide range of countries, with the vast majority of its revenue coming from exports. Listed on KOSDAQ, Korea's tech and small-cap board, the company derives most of its sales from fetal and neonatal devices, though it has been steadily expanding into home-use and general medical equipment.
Summary is AI-generated and may contain errors · figures from DART filings
Bistos describes itself as the sole domestic Korean supplier of fetal heartbeat monitors, supplying them directly to expectant mothers as well as to medical facilities.
Bistos in five facts
What does Bistos do?
Bistos makes medical devices that monitor and care for unborn babies and newborns, including fetal heartbeat monitors, jaundice treatment units, and infant incubators, as well as breast pumps and general patient-monitoring equipment for broader clinical and home use.
Where is Bistos listed and in which sector?
Bistos (Korean name: 비스토스) trades under KRX code 419540 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Bistos?
Its market capitalisation was US$12.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Bistos's latest annual revenue and operating profit?
For fiscal year 2025, Bistos reported revenue of US$12.9M, an operating loss of US$826.9K and a net loss of US$527.7K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 15.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Results of extraordinary shareholders' meetingOct 12
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 23
- Proxy solicitation reference documentSep 23
- Notice of general shareholders' meetingSep 23
- [Amended] Material event report (convertible bonds)
Bistos updated the terms of convertible bonds to raise US$2.82M, about 23.8% of its market value.
Capital raise · Jul 31 · 2 versions - Material event report (decision to redeem own convertible bonds early)
Bistos decided on July 6, 2026 to redeem US$654K in face value of its Series 2 convertible bonds before maturity for US$690K, exercising a call option, leaving US$1.96M in face value outstanding out of the original US$2.62M issue.
Capital raise · Jul 6 - Securities issuance results (voluntary) (third-party placement)Capital raise · Jun 18
- Material event report (rights offering)
Bistos disclosed a private placement (third-party allotment) to raise US$2.3M, about 20.9% of its market value.
Capital raise · Jun 10 - Trading suspension (share consolidation/split registration)M&A · Apr 27
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Bistos reported separate results for FY2025: revenue of US$11.6M (−15.58% year on year), an operating loss of US$770K (from a profit a year earlier) and a net loss of US$491K (from a profit a year earlier).
Earnings · Mar 6 - Change of largest shareholderOwnership change · Jan 20